New Treatments & Clinical Trials for Muscular Dystrophy

Muscular dystrophy describes a group of genetic diseases that cause progressive muscle weakness and loss. Duchenne muscular dystrophy, the most common childhood form, affects about 1 in 5,000 boys. Treatment has focused on managing symptoms with corticosteroids, physical therapy, and heart and breathing support, though the FDA has approved several gene-targeted therapies in recent years.

What's actually going on in research

Trials are testing gene therapies that deliver working copies of dystrophin or micro-dystrophin genes, gene editing approaches using CRISPR to fix mutations, exon-skipping drugs that restore partial dystrophin production, and anti-inflammatory therapies to slow muscle damage. Work is also advancing for rarer forms like limb-girdle and facioscapulohumeral muscular dystrophy.

What to know before you search

Eligibility typically depends on dystrophy type, specific gene mutation, age, walking ability, and prior treatments including corticosteroids or gene therapies.

What types of trials are currently open

• Gene therapy trials — Testing one-time infusions that deliver working gene copies to muscle cells, aiming to restore dystrophin production.
• Exon-skipping trials — Testing drugs that help muscle cells skip over mutated gene sections and produce shortened but functional dystrophin.
• Gene editing trials — Using CRISPR or similar tools to directly repair gene mutations in muscle tissue.
• Anti-inflammatory trials — Testing drugs that reduce muscle inflammation and scarring to slow disease progression.
• Natural history studies — Following people with muscular dystrophy over time to track progression and identify treatment targets.